Advances in the clinical application of mesenchymal stem cells for neurological disorders.
Advances in the clinical application of mesenchymal stem cells for neurological disorders.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Abu Dhabi, AE · Author affiliation
Department of Health and Laboratory Sciences, College of Medical and Health Sciences, Liwa University, Al Ain, Abu Dhabi, United Arab Emirates.Location evidence
SA · Author affiliation · country only
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.Location evidence
Karbala, IQ · Author affiliation
Department of Clinical Laboratory Sciences, College of Pharmacy, University of Al-Ameed, PO Box 198, Karbala, Iraq.Location evidence
Riyadh, SA · Author affiliation
Department of Medical and Surgical Nursing, College of Nursing, Princess Norah Bint Abdurrahman University, Riyadh, Saudi Arabia.Location evidence
Abha, SA · Author affiliation
Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.Location evidence
Tabuk, SA · Author affiliation
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.Location evidence
Alexandria, EG · Author affiliation
Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Therapeutic approaches employing mesenchymal stem cells (MSCs) have emerged as a promising avenue for investigating treatments for neurological disorders. This strategy aims to capitalize on the biological properties of MSCs to support the repair of damaged neural tissue and modulate pathological processes. This review provides a comprehensive overview of the current clinical evidence regarding MSC applications in major neurological disorders, including Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, spinal cord injury (SCI), and other pertinent disorders. Across clinical studies, MSC administration has generally demonstrated a favorable safety profile and procedural feasibility. However, therapeutic efficacy remains variable and inconsistent across trials. Importantly, differences in MSC sources, manufacturing procedures, delivery routes, dosing strategies, and patient selection contribute substantially to the heterogeneity of reported outcomes. Therefore, the current body of evidence supports the safety of MSC-based interventions, but their clinical effectiveness has not yet been consistently demonstrated. Future progress will depend largely on the standardization of cell preparation and treatment protocols, improved biomarker-driven patient stratification, and rigorously designed large-scale randomized trials.